1. Patients launch $1.27 million crowdfunding campaign for ME/CFS gut microbiome study.
    Check out the website, Facebook and Twitter. Join in donate and spread the word!
Phoenix Rising Adds Two New Board Members
Mark Berry introduces the new President of Phoenix Rising, Dr. Gary Solomon, and welcomes Professor Jonathan Edwards to the Phoenix Rising Board of Directors.
Discuss the article on the Forums.

Epigenetic modification of the norepinephrine transporter in POTS

Discussion in 'Problems Standing: Orthostatic Intolerance; POTS' started by ramakentesh, Dec 19, 2012.

  1. ramakentesh

    ramakentesh Senior Member

    Messages:
    525
    Likes:
    81
    OBJECTIVE:

    The postural tachycardia syndrome (POTS) has multiple symptoms, chief among which are tachycardia, weakness, and recurrent blackouts while standing. Previous research has implicated dysfunction of the norepinephrine transporter. A coding mutation in the norepinephrine transporter gene (SLC6A2) sequence has been reported in 1 family kindred only. The goal of the present study was to further characterize the role and regulation of the SLC6A2 gene in POTS.
    METHODS AND RESULTS:

    Sympathetic nervous system responses to head-up tilt were examined by combining norepinephrine plasma kinetics measurements and muscle sympathetic nerve activity recordings in patients with POTS compared with that in controls. The SLC6A2 gene sequence was investigated in leukocytes from POTS patients and healthy controls using single nucleotide polymorphisms genotyping, bisulphite sequencing, and chromatin immunoprecipitation assays for histone modifications and binding of the transcriptional regulatory complex, methyl-CpG binding protein 2. The expression of norepinephrine transporter was lower in POTS patients compared with healthy volunteers. In the absence of altered SLC6A2 gene sequence or promoter methylation, this reduced expression was directly correlated with chromatin modifications.
    CONCLUSIONS:

    We propose that chromatin-modifying events associated with SLC6A2 gene suppression may constitute a mechanism of POTS.

    http://www.ncbi.nlm.nih.gov/pubmed/22723437
    voner and Valentijn like this.

See more popular forum discussions.

Share This Page